Anthony Iafrate

List of Publications by Year
in descending order

139 papers	18,815 citations	23567 58 h-index	15266 126 g-index
144 all docs	144 docs citations	144 times ranked	30754 citing authors

#	Article	IF	Citations
1	GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nature Biotechnology, 2015, 33, 187-197.	17.5	1,757
2	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA - Journal of the American Medical Association, 2014, 311, 1998.	7.4	1,386
3	Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell, 2021, 184, 2372-2383.e9.	28.9	1,166
4	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung Cancer. Cancer Discovery, 2016, 6, 1118-1133.	9.4	919
5	mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell, 2022, 185, 457-466.e4.	28.9	881
6	Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science, 2014, 345, 216-220.	12.6	808
7	Anchored multiplex PCR for targeted next-generation sequencing. Nature Medicine, 2014, 20, 1479-1484.	30.7	705
8	Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science, 2014, 346, 1480-1486.	12.6	635
9	COVID-19-neutralizing antibodies predict disease severity and survival. Cell, 2021, 184, 476-488.e11.	28.9	586
10	Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Science Immunology, 2020, 5, .	11.9	561
11	Resensitization to Crizotinib by the LorlatinibALKResistance Mutation L1198F. New England Journal of Medicine, 2016, 374, 54-61.	27.0	433
12	Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 2015, 5, 713-722.	9.4	429
13	Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusionâ€"Positive Cholangiocarcinoma. Cancer Discovery, 2017, 7, 252-263.	9.4	384
14	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine, 2019, 25, 1415-1421.	30.7	359
15	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discovery, 2018, 8, 1529-1539.	9.4	342
16	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
17	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell, 2015, 28, 773-784.	16.8	327
18	Recurrent and functional regulatory mutations in breast cancer. Nature, 2017, 547, 55-60.	27.8	269

#	Article	IF	Citations
19	Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib. Clinical Cancer Research, 2014, 20, 5686-5696.	7.0	261
20	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusionâ€"Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	9.4	254
21	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. Cancer Discovery, 2014, 4, 1299-1309.	9.4	207
22	FGFR1 Amplification in Squamous Cell Carcinoma of The Lung. Journal of Thoracic Oncology, 2012, 7, 1775-1780.	1.1	197
23	T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell, 2022, 185, 1041-1051.e6.	28.9	187
24	Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in HÃ¼rthle Cell Carcinoma. Cancer Cell, 2018, 34, 242-255.e5.	16.8	185
25	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. American Journal of Surgical Pathology, 2018, 42, 791-798.	3.7	182
26	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nature Genetics, 2020, 52, 371-377.	21.4	177
27	Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8001-8001.	1.6	176
28	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology, 2020, 38, 3883-3894.	1.6	168
29	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Nonâ€"Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 2017, 1-13.	3.0	158
30	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. Clinical Cancer Research, 2014, 20, 2898-2909.	7.0	146
31	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. Cancer Immunology Research, 2015, 3, 288-295.	3.4	145
32	Acquired Resistance to Crizotinib in NSCLC with MET ÂExon 14 Skipping. Journal of Thoracic Oncology, 2016, 11, 1242-1245.	1.1	140
33	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. Journal of the National Cancer Institute, 2020, 112, 1021-1029.	6.3	138
34	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research, 2016, 22, 1632-1641.	7.0	127
35	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine, 2016, 3, 54-66.	6.1	123
36	Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointestinal Endoscopy, 2016, 83, 140-148.	1.0	119

#	Article	IF	Citations
37	Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial. Journal of Molecular Diagnostics, 2017, 19, 313-327.	2.8	115
38	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist, 2015, 20, 1019-1027.	3.7	112
39	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clinical Cancer Research, 2016, 22, 4452-4465.	7.0	112
40	Clinicopathologic Features of Nonâ€"Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precision Oncology, 2018, 2018, 1-12.	3.0	112
41	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nature Communications, 2018, 9, 1474.	12.8	106
42	Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines. Journal of Infectious Diseases, 2022, 225, 1141-1150.	4.0	102
43	IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Research, 2016, 76, 7118-7129.	0.9	99
44	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical Cancer Research, 2019, 25, 2699-2707.	7.0	98
45	MET Exon 14 Skipping in Non-Small Cell Lung Cancer. Oncologist, 2016, 21, 481-486.	3.7	94
46	Implementing the DICOM Standard for Digital Pathology. Journal of Pathology Informatics, 2018, 9, 37.	1.7	93
47	Nextâ€generation sequencing adds value to the preoperative diagnosis of pancreatic cysts. Cancer Cytopathology, 2017, 125, 41-47.	2.4	86
48	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	86
49	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. Journal of the National Cancer Institute, 2017, 109, .	6.3	82
50	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clinical Cancer Research, 2019, 25, 158-165.	7.0	81
51	Panâ€cancer analysis of copy number changes in programmed deathâ€ligand 1 (PDâ€L1, CD274) â€" associations with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639.	2.8	80
52	Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy. Journal of Molecular Diagnostics, 2016, 18, 124-130.	2.8	79
53	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. Journal of Clinical Oncology, 2022, 40, 12-23.	1.6	75
54	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletionâ€"Mediated Cytotoxicity. Cancer Research, 2017, 77, 4102-4115.	0.9	74

#	Article	IF	Citations
55	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. Journal of Infectious Diseases, 2020, 222, 1955-1959.	4.0	72
56	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 1877-1885.	7.0	67
57	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathologica, 2018, 136, 779-792.	7.7	66
58	Structure-guided TÂcell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell, 2021, 184, 4401-4413.e10.	28.9	65
59	Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.. Journal of Clinical Oncology, 2012, 30, 7508-7508.	1.6	65
60	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discovery, 2018, 8, 417-427.	9.4	61
61	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. Npj Precision Oncology, 2017, 1, 5.	5.4	49
62	Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. Clinical Cancer Research, 2022, 28, 719-727.	7.0	46
63	High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Modern Pathology, 2015, 28, 552-563.	5.5	42
64	Genotype-targeted local therapy of glioma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8388-E8394.	7.1	40
65	Cellâ€free human papillomavirus DNA kinetics after surgery for human papillomavirusâ€"associated oropharyngeal cancer. Cancer, 2022, 128, 2193-2204.	4.1	35
66	A Nanopore Sequencingâ€"Based Assay for Rapid Detection of Gene Fusions. Journal of Molecular Diagnostics, 2019, 21, 58-69.	2.8	34
67	Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. Methods, 2015, 83, 118-127.	3.8	33
68	Blockade of transforming growth factorâ€Î² signaling enhances oncolytic herpes simplex virus efficacy in patientâ€derived recurrent glioblastoma models. International Journal of Cancer, 2017, 141, 2348-2358.	5.1	33
69	GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. Modern Pathology, 2017, 30, 1720-1727.	5.5	33
70	Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. Modern Pathology, 2019, 32, 511-523.	5.5	33
71	Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptorâ€"Positive Breast Cancer. Cancer Discovery, 2018, 8, 336-353.	9.4	32
72	Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencingâ€"Based Oncology Assays. Archives of Pathology and Laboratory Medicine, 2019, 143, 463-471.	2.5	32

#	Article	IF	Citations
73	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 661-668.	2.8	31
74	Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell, 2022, 40, 103-108.e2.	16.8	30
75	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. Scientific Reports, 2019, 9, 16830.	3.3	29
76	Defining genome-wide CRISPRâ€"Cas genome-editing nuclease activity with GUIDE-seq. Nature Protocols, 2021, 16, 5592-5615.	12.0	27
77	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clinical Cancer Research, 2019, 25, 4375-4387.	7.0	26
78	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nature Cancer, 2021, 2, 498-502.	13.2	26
79	High Lung Shunt Fraction in Colorectal Liver Tumors Is Associated with Distant Metastasis and Decreased Survival. Journal of Vascular and Interventional Radiology, 2014, 25, 1604-1608.	0.5	25
80	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. Npj Precision Oncology, 2019, 3, 18.	5.4	25
81	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro-Oncology, 2019, 21, 596-605.	1.2	25
82	Molecular characteristics of poorly differentiated chordoma. Genes Chromosomes and Cancer, 2019, 58, 804-808.	2.8	23
83	Isocitrate dehydrogenase 1 and 2 mutations, 2â€hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer, 2019, 125, 541-549.	4.1	23
84	Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma. Molecular Cancer Therapeutics, 2014, 13, 3210-3218.	4.1	21
85	Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma. Clinical Chemistry, 2015, 61, 1408-1416.	3.2	21
86	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942.	2.8	21
87	TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Acta Neuropathologica Communications, 2018, 6, 106.	5.2	18
88	Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Scientific Reports, 2015, 5, 10641.	3.3	17
89	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	17
90	Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.. Journal of Clinical Oncology, 2020, 38, 2502-2502.	1.6	17

#	Article	IF	Citations
91	Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist, 2019, 24, 193-201.	3.7	16
92	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1246-1262.	3.0	16
93	Clinical Validation of a Cell-Free DNA Gene Panel. Journal of Molecular Diagnostics, 2019, 21, 632-645.	2.8	15
94	Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics. Journal of Molecular Diagnostics, 2019, 21, 390-407.	2.8	15
95	Genome Editing: A Tool For Research and Therapy: Towards a functional understanding of variants for molecular diagnostics using genome editing. Nature Medicine, 2014, 20, 1103-1104.	30.7	14
96	Artificial Intelligence Approach for Variant Reporting. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	2.1	13
97	Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. Neuro-Oncology, 2019, 21, 1164-1174.	1.2	12
98	Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 4852-4862.	7.0	12
99	A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Advances, 2020, 4, 445-448.	5.2	11
100	Nanopore Flongle Sequencing as a Rapid, Single-Specimen Clinical Test for Fusion Detection. Journal of Molecular Diagnostics, 2021, 23, 630-636.	2.8	11
101	MYC Analysis by Fluorescent In Situ Hybridization and Immunohistochemistry in Primary Adrenal Angiosarcoma (PAA): a Series of Four Cases. Endocrine Pathology, 2015, 26, 334-341.	9.0	10
102	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3404-3413.	7.0	10
103	Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing. Archives of Pathology and Laboratory Medicine, 2021, 145, 415-418.	2.5	10
104	Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 1020-1020.	1.6	10
105	â€œMGMT for pt mgmtâ€• Is Methylguanine-DNA Methyltransferase Testing Ready for Patient Management?. Journal of Molecular Diagnostics, 2008, 10, 308-310.	2.8	9
106	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. Journal of Thoracic Oncology, 2019, 14, 835-843.	1.1	9
107	Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Scientific Reports, 2019, 9, 139.	3.3	9
108	Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay. American Journal of Clinical Pathology, 2021, 155, 748-754.	0.7	9

#	Article	IF	Citations
109	Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19. Virulence, 2022, 13, 890-902.	4.4	8
110	ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.. Journal of Clinical Oncology, 2012, 30, 7589-7589.	1.6	7
111	Detection of EWSR1 fusions in CCOC by targeted RNA-seq. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2022, 134, 240-244.	0.4	7
112	Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion. Oncologist, 2021, 26, 919-924.	3.7	6
113	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Advances, 2022, 6, 818-827.	5.2	5
114	Cytomorphologic characteristics of next-generation sequencingâ€"positive bile duct brushing specimens. Journal of the American Society of Cytopathology, 2020, 9, 520-527.	0.5	4
115	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2017, 35, 1046-1046.	1.6	4
116	Alliance A071701: Genomically guided treatment trial in brain metastases.. Journal of Clinical Oncology, 2020, 38, TPS2573-TPS2573.	1.6	4
117	An Analysis of Reference Laboratory Testing in a Large Urban Academic Medical Center: The Impact of New Molecular Diagnostic Technologies. Laboratory Medicine, 2007, 38, 472-475.	1.2	3
118	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 4128-4128.	1.6	3
119	MET Amplification in Esophageal Squamous Carcinoma. International Journal of Surgical Pathology, 2018, 26, 731-732.	0.8	2
120	Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.. Journal of Clinical Oncology, 2019, 37, 3016-3016.	1.6	2
121	A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).. Journal of Clinical Oncology, 2012, 30, 8522-8522.	1.6	2
122	Reply to T. Komiya et al. Journal of Clinical Oncology, 2012, 30, 3426-3426.	1.6	1
123	CCR 20th Anniversary Commentary: Molecular Pathology of ALK-Rearranged Lung Tumors. Clinical Cancer Research, 2015, 21, 5185-5187.	7.0	1
124	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. Neuro-Oncology, 2019, 21, vi111-vi111.	1.2	1
125	Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.. Journal of Clinical Oncology, 2021, 39, 1065-1065.	1.6	1
126	Clinical implementation of anchored multiplex PCR with targeted next-generation sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma.. Journal of Clinical Oncology, 2015, 33, 8095-8095.	1.6	1

#	Article	IF	Citations
127	HCP-12IMPROVING THE EFFICIENCY OF MOLECULAR TESTING FOR EXPEDITED BRAIN TUMOR PATIENT MANAGEMENT AND CLINICAL TRIAL ENROLLMENT. Neuro-Oncology, 2015, 17, v103.4-v104.	1.2	0
128	MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS. Neuro-Oncology, 2016, 18, vi113-vi113.	1.2	0
129	EPID-11. PROGRESSION OF IDH MUTANT GLIOMA AFTER FIRST RECURRENCE: DEVELOPMENT OF A FEASIBLE CLINICAL TRIAL ENDPOINT IN THE RECURRENT SETTING. Neuro-Oncology, 2018, 20, vi82-vi82.	1.2	0
130	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. Neuro-Oncology, 2019, 21, vi58-vi59.	1.2	0
131	Prospective evaluation of serial 2-hydroxyglutarate in acute myeloid leukemia (AML) to determine response to therapy and predict relapse.. Journal of Clinical Oncology, 2012, 30, 6606-6606.	1.6	0
132	Update on Glioma Treatments in the United States. Japanese Journal of Neurosurgery, 2013, 22, 590-596.	0.0	0
133	Clinical grade Â“SNaPshotÂ” genetic mutation profiling in multiple myeloma.. Journal of Clinical Oncology, 2014, 32, e19571-e19571.	1.6	0
134	Targetable signaling pathway mutations and progression of IDH-mutant glioma.. Journal of Clinical Oncology, 2014, 32, 2061-2061.	1.6	0
135	Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers.. Journal of Clinical Oncology, 2015, 33, 4043-4043.	1.6	0
136	ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9062-9062.	1.6	0
137	BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.. Journal of Clinical Oncology, 2018, 36, 9045-9045.	1.6	0
138	An artificial intelligence approach to variant calling of ALK resistance mutations.. Journal of Clinical Oncology, 2019, 37, 3079-3079.	1.6	0
139	Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors. Cancer Research, 2022, 82, P3-23-02-P3-23-02.	0.9	0